Apimeds shares rise 11.35% premarket after correcting clerical errors in merger agreement and certificate without altering material terms.

Apimeds Pharmaceuticals US Inc. surged 11.35% in premarket trading following the announcement of an amendment to its Form 8-K, correcting clerical errors in the Agreement and Plan of Merger and the Certificate of Designation. The company emphasized that the revisions were non-material and solely intended to reflect the accurate intent of the parties involved. While the disclosure itself was procedural, investors may have interpreted the correction as a step toward finalizing the merger without substantive changes to terms, reducing uncertainty and fueling optimism about the transaction’s progress. The premarket rally suggests market participants viewed the update as a positive development, despite the company’s assertion that no material disclosures were altered.